Atorvastatin: HMG-CoA reductase inhibitors (Statins)
-
Powerful LDL-C and TG level reduction
-
Effective primary and secondary prevention
-
Superiority in reaching the lipid goals according to ATP III for all Dyslipidemic patients.
-
Trusted safety and tolerability
-
Convenient flexible range of doses.
-
Offers renal protection and reversal of endothelial dysfunction versus Rosuvastatin.
Indication
-
Dyslipidemia (LDL-C above 190 mg/dl)
-
Secondary Prevention of cardiovascular disease (CVD)
-
Primary prevention of CVD in diabetic patients with more than 7.5% cardiovascular risk (CVR)
